Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by E. Hedrick
Bruton's Tyrosine Kinase (Btk) Inhibitor BGB-3111 Demonstrates High Very Good Partial Response (Vgpr) Rate in Patients With Waldenström Macroglobulinemia (Wm)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
A Head-To-Head Phase 3 Study Comparing BGB-3111 and Ibrutinib in Patients With Waldenström Macroglobulinemia
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
The BTK Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents
Haematologica
Hematology
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase
Inhibition of IgE-mediated Secretion From Human Basophils With a Highly Selective Bruton's Tyrosine Kinase, Btk, Inhibitor
International Immunopharmacology
Allergy
Immunology
Pharmacology
Ibrutinib: The First Bruton's Tyrosine Kinase Inhibitor
Prescriber
Pharmacology
Impact of Day-100 Response Post Autologous Stem Cell Transplantation (ASCT) in Waldenström Macroglobulinemia (WM)
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
PATIENT-REPORTED OUTCOMES (PROs) IN WALDENSTRÖM MACROGLOBULINEMIA (WM) PATIENTS TREATED WITH IBRUTINIB-RITUXIMAB IN THE INNOVATE STUDY
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Bruton's Tyrosine Kinase Inhibitor Restrains WNT Signaling in Chronic Lymphocytic Leukemia
Molecular Medicine Reports
Oncology
Genetics
Molecular Biology
Biochemistry
Cancer Research
Molecular Medicine
Waldenström Macroglobulinemia
